TORNA ALL’ELENCO

Effect of gender on the outcome of patients receiing niolumab for metastatic renal cancer: Results from a large study population in Journal of Clinical Oncology

2019
ASL Cuneo 2

Tipo pubblicazione

Conference Abstract

Autori/Collaboratori (20)Vedi tutti...

Procopio G

Di Cosimo S

De Giorgi U


et alii...

Abstract

Background: Several studies, the maority on melanoma and lung cancer, have addressed the value of gender with respect to immune check point inhibitors outcome as compared to standard therapy, showing conflicting results. Nevertheless, few focused on gender-related clinical outcome and toxicity in renal cell carcinoma (RCC) patients. Methods: This analysis evaluated the effect of gender on overall survival and adverse events (As) using Common Terminology Criteria for Adverse vents (CTCA) v.4.0 in an expanded access programme of nivolumab 3 mg/kg once every 2 weeks in second-line and beyond metastatic RCC. Only patients assuming at least one dose of nivolumab were analyed. Results: Of 389 patients analyed, 25.2% were female. On study entry, no differences were found in women as compared to men in terms of age, on average 64 years, p = 0.91; overweight/obesity, 45 versus (vs) 49%, p = 0.47; LDH , mean U/L 391 vs 32, p = 0.17); and neutrophils/lymphocytes ratio 3 (62 vs 63%, p = 0.87). Disease presentation was similar according to gender, although women tended to present less lung (66% vs 76%, p = 0.06) and bone metastases (42% vs 52%, p = 0.07). Notably, there was no differences in the IDMC prognostic model by gender (p = 0.94). Any drug related As (38 vs 30%, p 0.15), grade 3-4 (6% vs 6%) and median number of drug doses 12 (53% vs50%, p = 0.58 ) did not differ between gender. After adusting for known prognostic variables, multivariate analysis showed that women had similar overall survival as compared to men (haard ratio 0.81, 95% confidence interval 0.56-1.17, p = 0.26).Conclusions: Women demonstrate similar overall survival than men in metastatic RCC treated with secondal line and beyond nivolumab, with no differences observed in serious As and dose administered.

DOI : 10.1200/JCO.2019.37.15_suppl.e16087

Keywords

nivolumab; adult; adverse drug reaction; bone metastasis; cancer prognosis; cancer survival; compassionate use; conference abstract; controlled study; drug therapy; female; gender; human; human cell; kidney metastasis; lung cancer; lymphocyte; major clinical study; male; melanoma; neutrophil; nomenclature; obesity; overall survival; side effect;